BioArctic AB (BIOA_B) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Bioarctic Ab Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.336 Welcome to BioArctic Q2 Report 2025. For the first part of the conference call, 00:00:05.336 -- 00:00:07.979 the participants will be in listen-only mode. 00:00:07.979 -- 00:00:13.044 During the questions and answers session, participants are able to ask questions by dialing 00:00:13.044 -- 00:00:18.330 pound key 5 on their telephone keypad. Now I will hand the conference over to CEO 00:00:18.330 -- 00:00:24.014 Gunala Oswald and CFO Anders Martinloff. Please go ahead. 00:00:25.337 -- 00:00:30.462 Thank you. Good morning and welcome to BioArctic's presentation for the second quarter 00:00:30.462 -- 00:00:32.522 of 2025. 00:00:32.585 -- 00:00:37.993 Bioartic is now entering a new era. It's an era of profitable 00:00:37.993 -- 00:00:43.622 growth and I think it's signified by yet another strong quarter and 00:00:43.622 -- 00:00:47.768 a lot of activities throughout the different parts of the business. 00:00:47.768 -- 00:00:52.816 We see increasing Lecambi royalties and we are very 00:00:52.816 -- 00:00:56.358 pleased with the new partnership with Novartis. 00:00:56.360 -- 00:01:01.287 It's the third partnership utilizing our brain-transporter technology, and it's the first 00:01:01.287 -- 00:01:05.332 of its kind. And I'll talk more about that in today's presentation. 00:01:05.332 -- 00:01:07.793 Next slide, please. 00:01:07.916 -- 00:01:12.122 Biotic is listed at Nasdaq Stockholm large cap, and this is our disclaimer. 00:01:12.122 -- 00:01:14.642 Next slide, please. 00:01:14.906 -- 00:01:18.010 I'm Gunilla Asvold, and I'm the CEO of Biotic. 00:01:18.010 -- 00:01:23.017 And today, I will share the presentation with our CFO, Anders Martin Lööf, and 00:01:23.017 -- 00:01:28.090 also with our Chief R&D Officer, Johanna Felting, and our ...